Critical role of NF-κB in pancreatic cancer

Oncotarget

Volumn 5, Issue 22, 2014, Pages 10969-10975

  Prabhu, Lakshmi ^a   Mundade, Rasika ^a   Korc, Murray ^a,b   Loehrer, Patrick J ^c   Lu, Tao ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Joseph E Walther Hall ^*  (United States)

^c Indiana Cancer Pavilion   (United States)

Author keywords

NF B; Pancreatic cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; K RAS PROTEIN; MICRORNA; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN P62; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR HES 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CDKN2A GENE; CELL INVASION; CELL PROLIFERATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HES1 GENE; HEY1 GENE; HUMAN; METASTASIS; NONHUMAN; ONCOGENE K RAS; P62 GENE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PTEN GENE; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SMAD4 GENE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; METABOLISM; PANCREAS CARCINOMA; PATHOLOGY;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; NF-KAPPA B;

EID: 84917710591     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2624     Document Type: Review

References (49)

1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986; 46:705-16.
2. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006; 25:6680-84.
3. Lenardo MJ, Pierce JW, Baltimore D. Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. Science. 1987; 236:1573-77.
4. Aggarwal B, Shishodiab S. Molecular targets of dietary agents for prevention and therapy of cancer. Science Direct. 2006; 71:1397-421.
5. Lu T, Sathe SS, Swiatkowski SM, Hampole CV, Stark GR. Secretion of cytokines and growth factors as a general cause of constitutive NF-κB activation in cancer. Oncogene. 2004; 23:2136-45.
6. Lu T, Stark GR. Cytokine secretion and constitutive NF-κB in cancer. Cell Cycle. 2004; 3:1114-7.
7. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene. 2000; 19:1123-31.
8. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut. 1996; 39:87-92.
9. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKß links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118:285-96.
10. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev. 2012; 246:379-400.
11. Kashani-Sabet M, Shaikh L, Miller JR, Nosrati M, Ferreira CM, Debs RJ, Sagebiel RW. NF-κB in the vascular progression of melanoma. J Clin Oncol. 2004; 22:617-23.
12. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006; 441:431-6.
13. Kern SE. Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med. Clin. North Am. 2000; 84:691-5.
14. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003; 4:437-50.
15. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20:1218-49.
16. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA. Both p16 (Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. 2006; 103:5947-52.
17. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2004; 17:3112-26.
18. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006; 20:3130-46.
19. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, Dry S, Wu H. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res. 2010; 70:7114-24.
20. Carrière C, Gore AJ, Norris AM, Gunn JR, Young AL, Longnecker DS, Korc M. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in pre-malignant lesions. Gastroenterology. 2011; 141:1091-101.
21. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
22. Preis M, Korc M. Signaling pathways in pancreatic cancer. Crit Rev Eukaryot Gene Expr. 2011; 21:115-29.
23. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993; 328:1433-7.
24. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer. 2003; 2:8.
25. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5:119-27.
26. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ. KrasG12D-induced IKK2/ß/ NF-κB activation by IL-1a and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21:105-20.
27. Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA, Hagemann T. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes PC progression in mice. J Clin Invest. 2011; 121:4685-99.
28. Liou GY, Döppler H, Necela B, Krishna M, Crawford HC, Raimondo M, Storz P. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. J Cell Biol. 2013; 202:563-77.
29. Chow JY, Ban M, Wu HL, Nguyen F, Huang M, Chung H, Dong H, Carethers JM. TGF-ß downregulates PTEN via activation of NF-κB in PC cells. Am J Physiol Gastrointest Liver Physiol. 2010; 298:275-82.
30. Shinohara H, Behar M, Inoue K, Hiroshima M, Yasuda T, Nagashima T, Kimura S, Sanjo H, Maeda S, Yumoto N, Ki S, Akira S, Sako Y, Hoffmann A, Kurosaki T, Okada-Hatakeyama M. Positive feedback within a kinase signaling complex functions as a switch mechanism for NF-κB activation. Science. 2014; 344:760-4.
31. Lu T, Tian L, Han Y, Vogelbaum M, Stark GR. Dosedependent cross-talk between the transforming growth factor-ß and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A. 2007; 104:4365-70.
32. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Büchler MW, Friess H. CXCL14 expression and potential function in PC. Cancer lett. 2008; 259:209-17.
33. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y. miR-301a as an NF-κB activator in PC cells. EMBO J. 2011; 30:57-67.
34. Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in PC cells. J Biol Chem. 2013; 288:15121-30.
35. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999; 18:6853-66.
36. Gilabert M, Calvo E, Airoldi A, Hamidi T, Moutardier V, Turrini O, Iovanna J. PC-Induced Cachexia Is Jak2- Dependent in Mice. J Cell Physiol. 2014; 229:1437-43.
37. Döppler H, Liou GY, Storz P. Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity. PLoS One. 2013; 8:e53676doi: 10.1371/journal.pone.0053676.
38. Gilmore T, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene. 2006; 25: 6887-99.
39. Gonzales A, Orlando R. Curcumin and resveratrol inhibit nuclear factor-κB-mediated cytokine expression in adipocytes. Nutr Metab. 2008; 5:17.
40. Qui X, Du Y, Lou B, Zuo Y, Shao W, Huo Y, Huang J, Yu Y, Zhou B, Du J, Fu H, Bu X. Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeeting nuclear factor-κB signaling pathway. J Med Chem. 2010; 53: 8260-73.
41. Venkateswararao E, Sharma V, Yun J, Kim Y, Jung S. Antiproliferative effect of chalcone derivates through inactivation of NF-κB in human cancer cells. Bioorg Med Chem. 2014; 22:3386-92.
42. Priyadarsini R, Murugan R, Maitreyi S, Ramalingam K, Karunagaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur J Pharm. 2010; 649: 84-91.
43. Kobayashi T, Yoshimori A, Kino K, Komori R, Miyazawa H, Tanuma S. A new small molecule that directly inhibits the DNA binding of NF-κB. Bioorg Med Chem. 2009; 7:5293-7.
44. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine D, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007; 109:3177-88.
45. Keifer J, Guttridge D, Ashburner B, Baldwin A. Inhibition of NFκB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem. 2001; 276:22382-7.
46. Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48 (Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia. 2012; 14: 778-87.
47. Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23:1254-63.
48. Lu T, Jackson MW, Singhi AD, Kandel ES, Yang M, Gudkov AV, Stark GR. Validation-based insertional mutagenesis to identify the FBXL11 as a negative regulator of NF-κB. Proc Natl Acad Sci USA. 2009; 106: 16339-44.
49. Wei H, Wang B, She Y, Gopalan B, Miyagi M, Stark GR, Lu T. PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci USA. 2013; 110:13516-21.